XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 27, 2024
Oct. 31, 2023
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2026
Dec. 31, 2024
Sep. 30, 2025
Jun. 27, 2025
Mar. 20, 2025
Nov. 30, 2024
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue       $ 966,630   $ 385,896   $ 1,360,202 $ 720,513              
Restricted Cash Equivalent, Current $ 1,588,384     1,588,384     1,588,384            
Restricted Cash Equivalent, Noncurrent 245,147     245,147     245,147            
Deferred Tax Asset, In-Process Research and Development 1,833,531     1,833,531       1,833,531                
Milestone payment         $ 250,000     250,000                
Revenue recognized amount               0                
Alphazyme [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Proceeds from sale maturity and collections of investments             $ 60,977       1,300,000          
Alphazyme [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Ownership percentage                               1.99%
Research and Development [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue       $ 213,449   $ 385,896   396,549 $ 720,513              
Gates Foundation [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Accounts receivable, after allowance for credit loss                             $ 3,092,136  
Proceeds $ 2,300,000                              
Total revenue         361,759     538,107                
Cost of revenue         349,558     492,849                
Gates Foundation [Member] | Forecast [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Proceeds                   $ 700,000            
CEPI [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue         141,422     175,545                
Cost of revenue         $ 115,576     $ 143,463                
Grant receivable                           $ 2,400,000    
CEPI [Member] | Fondazione Biotecnopolo Di Siena Fbs [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Grant receivable                           $ 4,500,000    
Proliant Agreement [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
License and development initial term   10 years                            
License and development extension term   3 years                            
Initial up front payment                         $ 500,000      
Second payment upon completion transfer                         $ 500,000      
Proliant Agreement [Member] | Forecast [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Final payment upon meeting certain productivity threshold                       $ 500,000        
Inzymes Agreement Aps [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
NonrefundableUpfrontPaymentReceived     $ 600,000                          
Deferred license revenue                     890,169          
Inzymes Agreement Aps [Member] | Research and Development [Member]                                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                
Total revenue                     $ 25,000